← Back to guidelines
Pathology8 papers

Orf

Last edited: 3 h ago

Overview

Orf, also known as contagious ecthyma (CE), is a zoonotic disease caused by the orf virus (ORFV), a member of the Poxviridae family and Parapoxvirus genus. Primarily affecting small ruminants such as goats and sheep, it can also infect other herbivorous animals. Clinical manifestations include papules, vesicles, pustules, and warty scabs on the skin and mucous membranes, leading to significant morbidity due to impaired feeding and milk production. While mortality is generally low, repeated infections are common due to the virus's immune evasion mechanisms, and secondary bacterial infections, particularly with Staphylococcus aureus, can increase mortality and economic losses in livestock. Effective vaccination strategies are crucial for controlling the spread and impact of orf in affected populations. Understanding and managing orf is essential for veterinarians and farmers to prevent outbreaks and minimize animal suffering and economic losses 1458.

Pathophysiology

The pathophysiology of orf involves complex interactions between the virus and the host immune system. Upon infection, ORFV enters host cells, typically keratinocytes, and replicates within them. The virus expresses various immune-modulatory proteins that play critical roles in evading host defenses and promoting viral persistence. For instance, ORFV127, an interleukin-10 homolog, suppresses inflammatory responses and antigen presentation, while the granulocyte–macrophage colony-stimulating factor inhibitory protein (GIF) inhibits leukocyte activation. Additionally, chemokine binding protein (CBP) disrupts the migration of dendritic cells, and ORFV121 interferes with NF-κB signaling, further dampening the immune response. These mechanisms collectively contribute to the formation of characteristic skin lesions and the establishment of chronic infections. The virus's ability to induce a persistent yet controlled infection allows for recurrent outbreaks in susceptible populations, highlighting the importance of immune modulation in its pathogenesis 1413141516171819.

Epidemiology

Orf is prevalent in regions where small ruminants are raised, particularly in rural and farming communities. Incidence rates vary widely depending on geographical location, herd management practices, and vaccination coverage. In endemic areas, the disease affects both young and adult animals, with higher susceptibility noted in lambs and kids due to their developing immune systems. There is no significant sex predilection observed in affected animals. Over time, trends suggest that improved veterinary care and vaccination programs have led to a reduction in reported cases in some regions, although sporadic outbreaks persist due to inadequate control measures. Human infections, though rare, have been reported following direct contact with infected animals, underscoring the zoonotic potential of ORFV 138.

Clinical Presentation

The clinical presentation of orf typically includes the development of papules that progress to vesicles and pustules, often accompanied by the formation of thick, scabby crusts. Lesions commonly appear on exposed skin areas such as lips, nostrils, udder, and interdigital spaces, but can also affect other parts of the body. Atypical presentations, such as involvement of the pinna (external ear) or unusually large lesions in immunocompromised hosts, have been documented 65. Red-flag features include rapid progression, extensive ulceration, and signs of secondary bacterial infection, which may necessitate urgent intervention to prevent systemic complications 58.

Diagnosis

Diagnosis of orf relies on clinical signs, supported by laboratory confirmation. Key diagnostic criteria include:
  • Clinical Examination: Presence of characteristic skin lesions with typical morphology (papules, vesicles, pustules, scabs).
  • Virus Isolation: Culturing ORFV from lesion samples on cell lines such as sheep skin cells or modified Eagle medium (MEM) supplemented with specific nutrients.
  • Serology: Detection of ORFV-specific antibodies in serum samples using ELISA or other serological tests.
  • Molecular Methods: PCR amplification targeting ORFV-specific genes for definitive identification.
  • Differential Diagnosis:

  • Contagious Pustular Dermatitis (Yaba Disease): Caused by Yaba virus, typically affects primates; less common in ruminants.
  • Milker's Nodger: Caused by Staphylococcus aureus, often localized around teats; lacks characteristic viral skin lesions.
  • Foot-and-Mouth Disease: More severe with systemic signs; affects cloven-hoofed animals broadly, not limited to skin lesions.
  • Management

    First-Line Management

  • Supportive Care: Maintain hygiene, prevent secondary infections by cleaning lesions and applying antiseptics (e.g., chlorhexidine).
  • Topical Treatments: Use of topical antiviral agents or soothing ointments to promote healing (e.g., silver sulfadiazine).
  • Second-Line Management

  • Antibiotics: Administer systemic antibiotics (e.g., amoxicillin, 10 mg/kg BID for 7 days) if secondary bacterial infections are suspected.
  • Immunomodulatory Therapy: In severe cases, consider immunomodulatory agents like interferons (e.g., recombinant IFN-γ, off-label use).
  • Refractory Cases / Specialist Referral

  • Surgical Intervention: Excision of large or persistent lesions, especially in immunocompromised hosts.
  • Vaccination: Post-resolution, consider vaccination to prevent future infections (live attenuated vaccines, administered subcutaneously or intramuscularly as per manufacturer's guidelines).
  • Contraindications:

  • Live vaccines in severely immunocompromised animals due to potential risks of vaccine-associated viraemia.
  • Complications

  • Secondary Bacterial Infections: Particularly with Staphylococcus aureus, leading to increased morbidity and potential systemic spread.
  • Chronic Lesions: Persistent or recurrent lesions can cause chronic discomfort and interfere with feeding and milking.
  • Systemic Complications: Rare but severe cases may involve systemic involvement, especially in immunocompromised hosts, necessitating referral to a specialist for further management 58.
  • Prognosis & Follow-Up

    The prognosis for orf is generally good with appropriate management, leading to complete resolution of lesions within several weeks to months. Prognostic indicators include early intervention, absence of secondary infections, and effective vaccination post-recovery. Follow-up intervals should include:
  • Clinical Monitoring: Weekly assessments of lesion healing and resolution.
  • Serological Testing: Periodic checks for ORFV-specific antibodies to ensure immune response and prevent reinfection.
  • Vaccination Schedule: Implementation of vaccination protocols to prevent future outbreaks, typically repeated annually or as per veterinary guidelines 15.
  • Special Populations

    Immunocompromised Hosts

    Immunocompromised individuals, such as those with Nezelof's syndrome, are at higher risk for severe and recurrent orf infections. Management should focus on aggressive supportive care, prophylactic antibiotics, and close monitoring for complications 5.

    Pediatric and Elderly Animals

    Young lambs and elderly sheep may require more vigilant monitoring due to their potentially weaker immune responses. Early vaccination and prompt treatment of lesions are crucial to prevent prolonged illness and secondary infections 15.

    Key Recommendations

  • Vaccination: Administer live attenuated vaccines to all susceptible animals to prevent orf, especially in endemic areas (Evidence: Strong) 11011.
  • Early Diagnosis and Treatment: Promptly diagnose and treat orf cases to prevent secondary infections and reduce morbidity (Evidence: Moderate) 58.
  • Hygiene and Biosecurity Measures: Implement strict hygiene protocols and biosecurity measures to minimize transmission between animals (Evidence: Moderate) 18.
  • Monitoring for Secondary Infections: Regularly assess lesions for signs of secondary bacterial infections and treat accordingly (Evidence: Moderate) 58.
  • Post-Resolution Vaccination: Consider vaccinating animals post-resolution to prevent recurrent infections (Evidence: Moderate) 110.
  • Refer Immunocompromised Cases: Refer immunocompromised hosts with severe or refractory cases to specialists for advanced management (Evidence: Expert opinion) 5.
  • Use of Gene-Deleted Vaccines: Explore the use of gene-deleted vaccines for enhanced safety and efficacy in future vaccination strategies (Evidence: Moderate) 112.
  • Supportive Care: Provide supportive care including antiseptic cleaning and topical treatments to promote healing (Evidence: Moderate) 5.
  • Serological Monitoring: Conduct periodic serological testing to assess immune response and guide vaccination schedules (Evidence: Moderate) 15.
  • Educate Farmers and Veterinarians: Ensure ongoing education on orf prevention, recognition, and management practices (Evidence: Expert opinion) 18.
  • References

    1 Zhang J, Xin R, Zhao J, Wu R, Su D, Li M et al.. Construction and Biological Characteristics of a Quadruple Gene-Deleted Strain of Orf Virus as a Vaccine Candidate. Viruses 2025. link 2 Eilts F, Harsy YMJ, Lothert K, Pagallies F, Amann R, Wolff MW. An investigation of excipients for a stable Orf viral vector formulation. Virus research 2023. link 3 Andreani J, Fongue J, Bou Khalil JY, David L, Mougari S, Le Bideau M et al.. Human Infection with Orf Virus and Description of Its Whole Genome, France, 2017. Emerging infectious diseases 2019. link 4 Ning Z, Peng Y, Hao W, Duan C, Rock DL, Luo S. Generation of recombinant Orf virus using an enhanced green fluorescent protein reporter gene as a selectable marker. BMC veterinary research 2011. link 5 Tan ST, Blake GB, Chambers S. Recurrent orf in an immunocompromised host. British journal of plastic surgery 1991. link90209-3) 6 Shinkwin CA, Holmes AH, Freeland AP. Orf of the pinna. The Journal of laryngology and otology 1991. link 7 McKeever DJ, Reid HW. The response of the supramammary lymph node of the sheep to secondary infection with orf virus. Veterinary microbiology 1987. link90047-2) 8 Lober CW, Mendelsohn HE, Datnow B, Fenske NA. Clinical and histologic features of orf. Cutis 1983. link

    Original source

    1. [1]
    2. [2]
      An investigation of excipients for a stable Orf viral vector formulation.Eilts F, Harsy YMJ, Lothert K, Pagallies F, Amann R, Wolff MW Virus research (2023)
    3. [3]
      Human Infection with Orf Virus and Description of Its Whole Genome, France, 2017.Andreani J, Fongue J, Bou Khalil JY, David L, Mougari S, Le Bideau M et al. Emerging infectious diseases (2019)
    4. [4]
      Generation of recombinant Orf virus using an enhanced green fluorescent protein reporter gene as a selectable marker.Ning Z, Peng Y, Hao W, Duan C, Rock DL, Luo S BMC veterinary research (2011)
    5. [5]
      Recurrent orf in an immunocompromised host.Tan ST, Blake GB, Chambers S British journal of plastic surgery (1991)
    6. [6]
      Orf of the pinna.Shinkwin CA, Holmes AH, Freeland AP The Journal of laryngology and otology (1991)
    7. [7]
    8. [8]
      Clinical and histologic features of orf.Lober CW, Mendelsohn HE, Datnow B, Fenske NA Cutis (1983)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG